You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a novel accurate therapy for Multiple Sclerosis
SBC: Autoimmunity Biologic Solutions, Inc. Topic: NIAIDPROJECT SUMMARY Multiple SclerosisMSis the most common neurological disease of early adulthood and is mediated by autoimmune mechanisms that lead to demyelination and neuronal damage in the central nervous systemresulting in progressive neurological dysfunctionUp to datethere is no cure for the disease and current available treatments focus on preventing future immunological attacksprimarily by su ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Direct-read monitor for airborne viral pathogens
SBC: AEROSOL DEVICES INC Topic: NIAIDAerosolized pathogenssuch as Influenza virusescan spread rapidly and silently throughout a populationcausing severe outbreaks that can be difficult to controlEarly detection of these airborne pathogens is key to controlling outbreaksespecially among vulnerable populations such as in hospitalstreatment centers or nursing homesYet available methods are neither rapidnor portableCurrent methods rely h ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
BlueBox: A Complete Code Blue Data Recorder, Phase II
SBC: NeoVative, Inc. Topic: 400“Code blue” is the signal used in hospitals to call for an immediate cardiopulmonary resuscitation (CPR) following a cardiac or respiratory arrest. Reviewing the performance of the “code blue team” is a cornerstone for improving outcomes. The current standard of using handwritten records on a paper “code sheet” does not allow measurement of key quality indicators and is subject to huma ...
STTR Phase II 2019 Department of Health and Human ServicesNational Institutes of Health -
AHTP-comet: development of an automated, high throughput comet assay system
SBC: ENGINEERING RESOURCES GROUP INC Topic: NIEHSPROJECT SUMMARY Genomic instabilityinduced by DNA damageand partly mitigated by DNA repair and antioxidantsplays a critical role in the pathogenesis of many major human diseasessuch as neurodegenerationcancer and cardiovascular diseasetogether with agingThere is a critical need for automated assays that can perform these assessmentsand bring them into greater routine usewhich will help advance our ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Integrin Activation as a Treatment for Leukocyte Adhesion Deficiencies
SBC: 7 Hills Pharma LLC Topic: NIAIDLeukocyte adhesion deficiency type ILADis a rare and often fatal primary immunodeficiencyIt is caused by autosomal recessive mutations in the gene ITGBwhich encodes CDthe commonsubunitof thefamily of integrin cell adhesion molecules that are specifically expressed on cells of hematopoietic origin like leukocytesAs a result of decreased function ofintegrinsleukocytes cannot extravasate from the vas ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
High-Throughput Assay for Profiling Alternative Splicing and Splicing Regulators
SBC: Biospyder Technologies, Inc. Topic: 172SummaryThis Phase I program will develop TempO Splicea highly multiplexed targeted sequencing assay monitoring RNA Binding ProteinRBPsplicing expression and alternatively splicedASmRNA representatives of coregulated splicing modulesa novel variation of the TempO Seqassay used for high throughput screeningdesigned to address the hypothesis that it is possible to provide a surrogate assay of the who ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Bone Metastasis Specific 18F PET Imaging Probe for Breast Cancer
SBC: BIOVINC, LLC Topic: 102ABSTRACTBreast CancerBCis the leading cause of cancer death for woman in the USBreast cancer is treated by a combination of surgeryradiationand various types of chemo and targeted therapeutic strategiesApproximately half of patients who have positive sentinel lymph nodes at surgeryand as many asof patients who do noteventually present with metastatic diseaseOverof BC patients eventually have skele ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Rapid Development of a Highly Specific Dengue Diagnostic Test
SBC: Z-Quick, LLC Topic: NIAIDProject Summary Abstract The advent of the Zika virusZIKVepidemic around the world has and will cause problems for the correct diagnosis of flavivirus infectionsFor many yearsDENV serological diagnosis was relatively straightforwardHoweverafter the recent ZIKV epidemiccross reactive antibodiesAbsgenerated after ZIKV infection will bind to DENV even if the patient has never had DENVThe only FDA app ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Stem Cells for Treating Acute Stroke
SBC: SANERON CCEL THERAPEUTICS, INC. Topic: 999ABSTRACT SUMMARY In previous studies we identified novel non hematopoietic umbilical cord blood stem cellsnhUCBSCsthat could be expanded to high passages and exhibit restorative properties following ischemic brain injury repairWe found that the high passaged cells were equivalentif not even betterthan the low passaged nh UCBSCsThis finding suggests that these cells can serve as a source of highly ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health -
Urocortin-2 Gene Transfer for Type 1 Diabetes and Associated LV Dysfunction
SBC: Renova Therapeutics, Inc. Topic: NHLBIABSTRACT TypeDiabetes MellitusT DMaffectsmillion patients in US withnew patients annuallyLifespan is shortenedyearsdue to kidney and heart diseaseTight glucose control reduces microvascular complications and adverse cardiovascular eventsInsulin therapy is essential for such patientsbut has shortcomingsaonlyinpatients achieve targeted glucose controlHbA c andltbaggressive insulin therapy increases ...
STTR Phase I 2019 Department of Health and Human ServicesNational Institutes of Health